Induction of a systemic response by in vitro-generated cDCV using CD103+cDC1 cells and OS lysates with successful infiltration of activated T-cells into the center of the tumor suggests that cDCV therapy may be able to circumvent the immunosuppressive tumor microenvironment, which has limited the activity of current immunotherapies for this cancer. Here, ITGAE is linked to cancer.